ev Transportation Services Inc.

The QualityStocks Daily Newsletter would like to spotlight ev Transportation Services Inc.

ev Transportation Services (“evTS”), an electric vehicle manufacturer focused on the essential services and urban mobility markets, today announced its participation in the upcoming Fifth Annual Needham Virtual Automotive Tech Conference. Per the update, evTS chairman and CEO David Solomont has been invited to participate in a fireside chat with Needham analyst Alex Salisbury at 1:15 p.m. ET on Tuesday, June 8, 2021. Solomont will also meet with the investment community in a series of virtual one-on-one meetings during the week of June 8, reviewing the company’s market entry plans and strategy for growth. Interested parties should visit https://ibn.fm/512xt to register for the event and access the webcast. An archived replay of the webcast will be available on the evTS website following the live event. To view the full press release, visit https://ibn.fm/jbbWw

ev Transportation Services Inc. (“evTS”) is a designer, developer and manufacturer of all-electric lightweight commercial vehicles and fleet management solutions.

Founded in 2015 in Brookline, Massachusetts, and currently based in Boston, the company is focused on the essential transportation services market. End-user applications for evTS vehicles include services such as security, parking enforcement, local small package delivery, meter reading, sanitation, parks and recreation, university and corporate campuses, and warehouse operations.

The FireFly ESV(R)

The company’s flagship product is the FireFly ESV(R), a high-performance, low-maintenance electric vehicle with zero emissions. This utility vehicle was created specifically to meet the needs of essential services users. The FireFly ESV utilizes the safest Lithium Ion battery technology available (LiFePO4, Lithium Iron Phosphate) for superior acceleration, improved energy efficiency and enhanced reliability. As a result, it boasts a range of 100+ miles on a single charge, further than any other electric vehicle in its class.

Additionally, its design can be modified according to the requirements of virtually any task and application, from parking enforcement and security to property and grounds maintenance, last mile urban delivery, on-campus tasks and more.

Parking Enforcement

The ideal parking specific vehicle (PSV), FireFly can be equipped with features that enable parking enforcement officers to do their jobs more effectively, significantly reducing operating costs while fully integrating with existing parking enforcement systems, including advanced license plate recognition programs. Key design features of the FireFly ESV that are critical for the successful execution of parking control tasks include:

• High maneuverability with a tight turning radius and slim design, allowing the vehicle to maneuver on narrow streets and park in compact urban environments;
• Electronically governed speeds of up to 50 mph in just seconds, allowing operators to quickly enter and keep up with fast moving traffic;
• Full-height DuraGlide(TM) doors and low steps allowing for rapid ingress and egress on both sides of the vehicle;
• Superior impact protection featuring an integrated safety cage and seatbelts;
• A modular bed design allowing users to include a lockable or sectional bed to make room for boots, parking cones and other equipment; and
• Friendly size and appearance, helping change the public’s perception of parking enforcement efforts.

Security

Specifically designed for flexible and quiet operation at low speeds, the FireFly ESV is an ideal vehicle for security and perimeter patrol tasks in different environments, including cities, office buildings, retail malls, prisons and educational institutions. With a range of 100+ miles, it allows security officers to patrol for the duration of an entire shift before returning to dispatch to recharge, thus generating savings compared to fuel-powered patrol vehicles. Key features that give the FireFly ESV a significant edge over its competition in security applications include:

• Agility and speed, allowing officers to provide rapid response and engage in light pursuit at speeds exceeding 50 mph;
• Comfort and security for the driver with the help of its tubular 2” steel roll cage and three-point safety harness;
• High maneuverability with a 20-plus-degree approach angle and 6” of curb clearance, along with a tight turning radius; and
• Low energy, high intensity lighting features for traffic control while idle for several hours.

Property and Grounds Maintenance

As a durable, customizable vehicle with minimal environmental impact, the FireFly ESV can be used for a wide range of maintenance operations on sidewalks and in recreation areas on a daily basis. Key features include:

• A customizable modular design allowing the vehicle to be built according to use specific maintenance requirements, with features such as a sectional bed, an electronic lift dump, a refuse hauler, a van box, a utility bed with locking compartments and ladder racks, and other cleaning, sweeping or watering accessories;
• A strong tubular steel frame and robust suspension design including the company’s proprietary DuraSteer(TM) front end featuring best-in-class anti-dive control and 1,100 pounds of payload capacity; and
• A light, three-wheel design offering a tight turning radius and a small footprint, allowing FireFly to maneuver in landscaped areas, navigate around pylons and bollards, and operate in narrow corridors, indoors or out.

Last Mile Urban Delivery

Designed for short-range trips with stop-and-go driving, the 100% Electric FireFly ESV is ideal for delivery services in crowded urban environments, being able to accommodate anything from small packages and food delivery to spare parts, medical deliveries and more. Key features that make the vehicle a top choice for delivery services include:

• More cargo space and hauling power than its competitors, due to its modular bed design and 1,100-pound payload capacity;
• Speed and efficiency, as a fully licensable and street legal vehicle that can reach governed speeds of up to 50 mph;
• Durability and maneuverability, making it a valuable addition to any delivery service’s vehicle fleet; and
• Exceptionally low cost of operation, as a virtually maintenance-free vehicle with long-lasting battery power.

The Firefly ESV 2021 Model

On September 15, 2020, the company announced the new 2021 model of its Firefly ESV vehicle. This model will retain all of its predecessor’s original components, with added features for the new 2021 line. The upgrades and new features include, but are not limited to:

• Larger door for easier vehicle access;
• More legroom within the cab;
• Improved visibility through the redesigned windshield;
• New rear bed accessory attachment options to better accommodate specific service industries; and
• An optional trailer hitch with electronic braking control.

Each vehicle will also be equipped with the evTS Connected Vehicle System, which includes in-vehicle Wi-Fi, an internet-accessible vehicle management system, the ability to perform remote diagnostics, low battery alerts and optional 360-degree video monitoring that runs in real-time.

In a news release, David Solomont, CEO of evTS, stated, “The 2021 FireFly is our best and most advanced model yet and will enable evTS to fill the critical and rapidly expanding need for essential service vehicles, particularly for last-mile on-demand urban delivery vehicles.”

Deal with ADOMANI

In April 2020, ADOMANI Inc. (OTCQB: ADOM) signed a letter of intent to purchase 120 FireFly ESV vehicles from evTS. Under the agreement, ADOMANI, a leading provider of zero-emission purpose-built electric vehicles and drivetrain solutions, serves as a distributor of current and future evTS electric vehicle offerings in the state of California.

In addition, ADOMANI may perform final assembly and testing activities of evTS vehicles, as well as warranty repair services, at its recently-opened assembly factory in Corona, California – a location that’s close to urban centers and a variety of terrains where the FireFly ESV can be utilized, according to ADOMANI COO Rick Eckert.

“The agreement with ADOMANI represents a major milestone for evTS, and we are excited to explore a partnership with them,” Solomont added. “Our FireFly ESV all-electric lightweight commercial utility vehicle is a perfect complement to their existing lineup of EVs, and we expect to significantly expand our sales in California and surrounding states based on the quality and reach of ADOMANI’s sales, service and support organization.”

Electric Vehicle Market

In 2019, the global electric vehicle market was valued at $162.34 billion. Registering a CAGR of 22.6%, the market is projected to reach $802.81 billion by 2027, according to an Allied Market Research report (https://nnw.fm/JAMbl).

Essential services fleet vehicles represent a replacement market of approximately 100,000 vehicles. These vehicles roughly translate to a $2.5-billion market opportunity each year.

Management Team

David Solomont is the Founder and CEO of evTS. He has over 40 years of experience in information technology, software and interactive media. He is an active investor and advisor to early-stage tech companies. Solomont has a bachelor’s degree in engineering from Tufts University and a master’s degree in management from MIT’s Sloan School.

Greg Horne is the Chief Technology Officer at evTS. He directs the company’s vehicle development efforts and is responsible for the new model year of the FireFly ESV being brought to market. He previously served as CTO of eFleets Corporation, worked on software and flight testing for the Bell/Boeing V-22 Osprey and served as a design engineer at Bell Helicopter.

Jim Sabitus is the company’s Vice President of Operations. He has experience as a corporate executive leading emerging and established publicly traded companies. Sabitus’ previous roles include CEO of Row One Brands Inc., CFO of Modern Shoe Company and various management roles at Converse Inc.

Paul Barrett is evTS’ Vice President of Marketing and Product. He is an experienced senior executive and serial entrepreneur with 45 years of experience in the automotive and electronics industries. His prior roles include serving as COO of Fixed Ops Pros, NavResearch and Cimble Corporation. Barrett also held numerous executive positions during his 20+ years at LoJack Corporation.

Eric Burmeister is the company’s Vice President of Sales and Business Development. He has held a number of positions within the specialized vehicle industry. Prior to joining evTS, he was the Director of National Sales and Business Development for Westward Industries. Burmeister also held national and regional sales positions for eFleets, Global Electric Motors and ZENN Motor Company.

Michael Tepfer is the company’s Vice President of Manufacturing Engineering. He is also the current president of Integrity Global Manufacturing Ltd. He has 30 years of experience in project management and oversight of overseas manufacturing businesses.

Todd Marcucci is evTS’ Director of Customer Satisfaction. He is a former Vice President of Research and Development for eFleets. He assembled and led a team that designed, supported and produced the original FireFly ESV. Marcucci has worked as a consultant for numerous projects related to electric vehicle powertrains.

Recent News

• ev Transportation Services Inc. - QualityStocksNewsBreaks – ev Transportation Services Inc. (‘evTS’) to Present at Upcoming Needham Virtual Automotive Tech Conference
• QualityStocksNewsBreaks – ev Transportation Services Inc. (‘evTS’) to Present at Upcoming Needham Virtual Automotive Tech Conference
• QualityStocksNewsBreaks – ev Transportation Services Inc. (‘evTS’) Enters Strategic Agreement with Leading EVSE Company

BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC)

The QualityStocks Daily Newsletter would like to spotlight BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC).

BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC), a diversified health and wellness beverage and natural products company, is staking target of the burgeoning alkaline water market with its TRACE line of products, which include natural spring alkaline water and plant-based mineral water. “What is not up for debate is the very real category growth of alkaline water,” reads a recent article. “Alkaline water is an emerging category that has caught consumer attention in the last decade, growing from a $325 million market in 2013 to $631 million in 2017, on a path to contribute billions to the broader global bottled water market. To view the full article, visit: https://cnw.fm/t4qVz. Also today, the company was featured in the 420 with CNW by CannabisNewsWire. When the first cannabis drinks hit the market a few years ago, they weren’t the smooth, high-quality beverages we see today. The cannabis industry itself was still in its infancy, cannabis technology was sorely lacking, and the results from these first attempts at infusing cannabis into beverages were not elegant. For instance, Lyden Henderson’s first run-in with a nonalcoholic, marijuana-infused beer last year left him with a bad taste in the mouth, literally.

BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) is a diversified health & wellness beverage and natural products company focused on developing and manufacturing a range of plant-based and cannabinoid beverages and supplements for both in-house brands and white-label clients. The BevCanna team boasts decades of experience creating, manufacturing and distributing iconic brands that resonate with consumers on a global scale.

BevCanna’s distribution network features more than 3,000 points of retail distribution through the company’s market-leading TRACE brand, its Pure Therapy natural health and wellness e-commerce platform, its fully licensed Canadian cannabis manufacturing and distribution network and its partnership with #1 U.S. cannabis beverage company Keef Brands.

Based in British Columbia, Canada, BevCanna was founded in 2017.

End-to-End Turnkey Beverage Manufacturing Solutions

BevCanna is a manufacturer of traditional and cannabis-infused beverage brands serving a growing roster of white-label clients, in addition to operating a portfolio of in-house and partner brands. The company offers a full-service white label beverage manufacturing solution.

• Processing – At its state-of-the-art beverage manufacturing facility, BevCanna partners with industry leaders specializing in crude extraction, refinement, purification and solubility conversion to provide high-quality water-immiscible emulsions that maximize bioavailability, clarity and taste.
• Spring Water – BevCanna directly owns a pristine naturally alkaline spring water aquifer in British Columbia.
• Product Development – BevCanna leverages its expertise to develop captivating flavors based on category and consumer insights in order to enhance product positioning.
• Packaging – A variety of packaging options are offered by BevCanna, including beverage and nutraceutical formats such as PET, aluminum and glass, available in a variety of standard and custom sizes and shapes.
• Beverage Manufacturing: Traditional & Cannabis Facilities – The company’s 40,000-square-foot beverage manufacturing facility is HACCP (Hazard Analysis Critical Control Point) Certified. The facility’s capabilities include blow molding, dosing, carbonation options, filling and capping, pressure sensitive and shrink-sleeve label applications, flash pasteurization, QA testing and packing/palletizing for shipment.

Pure Therapy, TRACE and Partner Brands

BevCanna’s in-house brands include Pure Therapy and TRACE.

Pure Therapy is a direct-to-consumer e-commerce brand that markets a range of natural health products, including nutraceuticals and hemp-based cannabidiol (CBD) products, throughout North America and Western Europe.

Pure Therapy has secured orders from over 23,000 customers since its inception in 2017. BevCanna expects strong growth through Pure Therapy over the next 12 months driven by new product integration, accelerated growth of existing products and its marketing team’s e-commerce expertise.

TRACE products feature the Naturo Group’s proprietary plant-based fulvic and humic mineral formula, sourced from deep within the Rocky Mountains of interior British Columbia. These unique and ancient minerals provide wellness properties that include iron, magnesium, calcium, potassium and many other minerals no longer found in our food chain at adequate levels.

Research suggests that the proprietary fulvic and humic organic compounds found in TRACE products could offer a number of key benefits, including promoting gut health, immune function, cognitive performance and whole-body wellness.

TRACE products include Natural Alkaline Spring Water, Plant-Based Mineralized Spring Water, Natural Flavor Sparkling Spring Water, Plant-Based Mineral Concentrate with Vitamin D and Plant-Based Mineralized Immune Support Shots.

In addition to its in-house brands, BevCanna provides white-label services to a number of partners in its space. BevCanna’s current portfolio of brand partnerships includes #1 U.S. cannabis beverage brand Keef (cannabis-infused classic soda) and BLOOM (live resin & high-end extracts). BevCanna also has multiple white label agreements to co-manufacture branded beverages.

Market Outlook for Cannabis-Infused Beverages

In 2018, the cannabis-infused beverage market was valued at $901.8 million. The market is expected to grow during the forecast period of 2019 to 2025 at a CAGR of 17.8%, resulting in a market value in excess of $2.84 billion by 2025, according to Grand View Research (https://ibn.fm/VkJfH).

The projected growth is largely attributed to the legalization of recreational and medical marijuana in multiple jurisdictions. Cannabis-infused beverages are uniquely positioned to provide an alternative to a large portion of the edibles market, including items such as chocolates, cookies, gummies and other types of confectionery pieces.

Management Team

Marcello Leone is the CEO and Founder of BevCanna. He is also the founder of Naturo Group and the TRACE brand.

John Campbell is the CFO and CSO of BevCanna. He has over 30 years of experience in the investment industry, including time with TriView Capital Ltd.

Keith Dolo is the company’s Executive Management Advisor, having previously served as CEO and Executive Chairman of Sproutly Inc. Previously, he served for over 13 years with Robert Half (NYSE: RHI), an S&P 500 company, specifically in the role of Vice President for the last eight years.

Melise Panetta is the company’s President. She is an accomplished senior marketing and sales executive with extensive experience leading organizations such as SC Johnson, General Mills (NYSE: GIS) and PepsiCo (NASDAQ: PEP). Ms. Panetta has nearly 15 years of deep marketing and sales expertise.

Raffael Kapusty is the company’s Vice President of Sales & Insights. She is an accomplished CPG industry leader with more than 25 years of experience in both the Canadian and U.S. retail spaces. With a solid foundation at ACNielsen Canada (NYSE: NLSN), Ms. Kapusty has developed a deep understanding of the CPG space, working with over 100 leading Canadian & global CPG manufacturers. She has also held senior category and key account management roles at Kroger (NYSE: KR), SC Johnson and Unilever Canada (NYSE: UL).

Bill Niarchos is the company’s Vice President of Sales & Sales Operations. He has over 20 years of experience in the CPG goods industry/retail environment. In his most recent role as Director of Sales with Bayer Consumer Health, Mr. Niarchos managed the strategic direction and growth of Loblaw & SDM. Prior to his position with Bayer (ETR: BAYN), Mr. Niarchos held a number of progressive roles at Colgate Palmolive (NYSE: CL) for more than 14 years.

Japheth Noah is the company’s Head of Quality Assurance. He is an Oxford and MIT educated quality and regulatory manager with over 15 years of experience in the beverage, pharmaceutical, natural health and medical industries.

Keith Stride is the company’s Creative Director. He has 25 years of experience in marketing and advertising, including time in a CMO role with Hemptown USA. Mr. Stride is internationally recognized for building high-profile brands, including Rogers (NYSE: RCI), TD Bank (NYSE: TD), Best Buy (NYSE: BBY), Whistler-Blackcomb and RBC (NYSE: RY).

BevCanna Enterprises Inc. (OTCQB: BVNNF), closed Friday’s trading session at $0.4112, up 2.80%, on 54,868 volume with 33 trades. The average volume for the last 3 months is 154,093 and the stock's 52-week low/high is $0.125/$1.20000004.

Recent News

• BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) - CannabisNewsBreaks - BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE:7BC) in Strong Position to Build TRACE Brand
• CannabisNewsBreaks - BevCanna Enterprises Inc.'s (CSE: BEV) (OTCQB: BVNNF) (FSE:7BC) TRACE Meets New Demographic Through Strategic Agreement
• 420 with CNW - Everything You Ought to Know About the Marijuana Entourage Effect

Asia Broadband Inc. (OTC: AABB)

The QualityStocks Daily Newsletter would like to spotlight Asia Broadband Inc. (AABB).

Since last year, conversation surrounding investments in the stock market has mainly been skeptical, even as economies across the globe slowly recover and open back up. This may explain why most investors are moving towards precious metals, such as silver and gold, which have a low correlation with the stock market and usually hold their value even in times of market volatility. If you aren’t sure whether you should include precious metals in your portfolio or how you can do so, below are a few things that you should know. All in all, you should ensure that your investment decisions are deliberate and carefully thought through so that you can see benefits from the investment in the long term. And given that there is a wide variety of precious metals sector players such as Asia Broadband Inc. (OTC: AABB) to choose from, investment opportunities aren’t hard to come by.

Asia Broadband Inc. (OTC: AABB) is a resource company focused on the production, supply and sale of precious and base metals, primarily to Asian markets.

The company utilizes its specific geographic expertise, experience and extensive industry contacts to facilitate its innovative distribution process from the production and supply of precious and base metals in Mexico to client sales networks in Asia. This vertically integrated approach to sales transactions differentiates Asia Broadband from its competitors in the mining space.

Development Program in Colima, Mexico

In October 2020, Asia Broadband announced its acquisition of a high potential mineral property in the state of Colima, Mexico. Per the press release, previous geophysics and groundwork have revealed strong indications of significant mineralization in multiple sectors of the property.

The company recently began the construction of exploration and development facilities and infrastructure roads on its Colima property, and plans are underway to extend previous geophysics and groundwork on the property. In January 2021, Asia Broadband announced its allocation of $10 million for the initial development program, with the aim of accelerating operations at the Colima site toward production.

Positioned in a major gold-iron-copper production area, the company’s Colima property is situated approximately 25 kilometers east of the Pena Colorada mine in Minatitlan, Mexico. It is advantageously located, with direct access to main Highway #3, and the property also has an essential natural water supply.

AABB Gold Token

In December 2020, Asia Broadband announced its entry into a definitive development agreement with Core State Holdings Corp., a digital assets and crypto wallet creator, to produce a white label gold-backed cryptocurrency coin. The AABB Gold token is an ERC-20 token being developed on the Ethereum blockchain.

In a February 2021 news release, the company provided a development update on the cryptocurrency token, noting that Core State Holdings Corp. “is continuing to modify the set-up and move through the final stages of testing of the iOS and Android AABB Wallet applications, including the implementation of an application interface to allow users to see the real-time exchange rate of gold that backs the price of the AABB Gold token set at one-tenth of a gram or approximately $5.80 USD.”

Core State Holdings Corp. has also continued to enhance www.AABBGoldToken.com, which the company notes will be the go-to knowledge base for all information concerning the soon-to-be launched AABB Wallet and AABB Gold token.

AABB’s primary goal for the token is to become a worldwide standard of exchange – secured and trusted with gold backing – by expanding circulation and targeting large population and high growth markets globally, including China and East Asia.

Asia Broadband Inc. (AABB), closed Friday’s trading session at $0.115, up 1.7699%, on 7,981,592 volume with 902 trades. The average volume for the last 3 months is 23.364M and the stock's 52-week low/high is $0.002099999/$0.658999979.

Recent News

• Asia Broadband Inc. (OTC: AABB) - Why It's Always Worthwhile to Invest in Precious Metals
• MiningNewsBreaks - Asia Broadband Inc. (AABB) Eyes Promising Assay Results in Leveraging Mine-to-Token Strategy
• China to Stabilize Metals Prices by Releasing Reserves

Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF)

The QualityStocks Daily Newsletter would like to spotlight Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF).

Chalice Farms will celebrate cannabis industry holiday, National Oil Day, with specials on cannabis concentrates, a collaboration with local artist, Damien Gilley, and a pop-up dab bus experience on Saturday, July 10. In honor of National Oil Day on Saturday, 7/10, which spells “OIL” upside-down, Chalice Farms will offer 30% off all dab products, 20% off all cartridges and discounts on products from Elysium Fields, Bobsled and White Label extracts from Friday, July 9 through Sunday, July 11. Chalice Farms will partner with local optical illusionist artist, Gilley, for an exclusive design across all Chalice Farms locations.

Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF) is a premier consumer-driven cannabis company powered by the Chalice retail and consumer brands. Chalice Brands takes a diversified approach to growth through innovation, strategic partnerships and retail expansion, as well as a brand portfolio focusing on health and wellness. The company features best in class retail cannabis experiences backed by cultivation, processing and developing wholesale distribution. With over 160 employees, Chalice Brands is one of the largest cannabis operators in Oregon. The company holds licensing in Oregon, as well as partnerships for manufacturing and distribution in California. Its current product portfolio includes recognizable brands such as Chalice(TM), Elysium Fields(TM), GOLDEN(TM), Jackpot(TM) and RXO(TM).

Brands

Chalice Brands offers an innovative product line that addresses current market needs and looks forward to meet emerging trends. The company’s goal is to offer something for everyone through the wholesale and retail marketplaces. Its current product offerings include:

Chalice(TM)
The Chalice Farms(TM) brand is focused on how cannabis enhances lives and ignites purpose. By offering the highest quality of cannabis in an array of flower, extracts, oils, edibles and full-body care products, the brand provides full efficacy in both the retail and wholesale markets. The Chalice Farms team has over 100 years of combined cannabis experience and continues to be an industry leader for both medical and recreational cannabis use – providing state-of-the-art farming practices, excellent retail and complete product innovation.

Elysium Fields(TM)
Elysium Fields(TM) is a “soil-to-oil” craft cannabis brand intended for cannabis connoisseurs who want the highest quality THC and boldest terpene flavors. Made from small-batch live resin, Elysium Fields creates an experience described as a remarkable entourage effect. The C-Cell cartridge has a 30% strain specific HTE with a 70% high THC distillate. The resin is created from a sustainable, organic garden flower that is flash-frozen upon harvest to preserve the terpenes for a heavenly experience.

RXO(TM)
RXO(TM) features Chalice Farms’ purest and most versatile Rick Simpson Oil products. RXO was developed by the Steele brothers in collaboration with medical professionals and is a potent, strain-specific Ethanol Hash Oil (EHO) purified through a proprietary process. Through this process, various consumption methods can be accommodated, including edible, topical, sublingual and smoking (shatter and vape).

GOLDEN(TM)
GOLDEN(TM) offers a wide variety of craft cannabis products for a diverse population of cannabis users. Sourced from the finest raw materials from local growers, GOLDEN products are high-quality and innovative. Premium cannabis distillate vaporizer cartridges and fruit chew edibles made from organic ingredients are made using the most flavorful terpenes for enhanced health, wellness and enjoyment. Products are distributed online and through Chalice Farms or other dispensary partners.

Jackpot(TM)
Jackpot(TM) products offer a powerful combination of flavor and potency. With 70% THC content in each cartridge, Jackpot adds full-spectrum cannabinoids and flavorful infused terpenes in short-run limited strains for on-the-go fun seekers. The quality hardware of the cartridges makes them easily recyclable and guarantees to produce a large volume draw each time.

Financial Results

On May 25, 2021, Chalice Brands announced its financial results for the first quarter of 2021. Among the highlights, the company reported:

• Record quarterly revenues from continuing operations of $5.5 million, marking an 18% year-over-year increase compared to $4.7 million for the same period in 2020.
• Gross profit for the three-month period of $2.5 million on 45% gross margin, compared to $1.7 million in gross profit on a 37% gross margin in 2020.
• Its second consecutive quarter of positive adjusted EBITDA, recording approximately $370,000, or 7%, and continuing to demonstrate that the company’s Oregon operations are capable of covering corporate overhead costs.

In announcing the results, Jeff Yapp, CEO of Chalice Brands, stated, “Continued profitable operations and accretive acquisitions should set us up for a record breaking second half of 2021. We continue to look forward to favorable federal regulation changes while we grow Fifth & Root to showcase our brand portfolio nationally. Our team is energized and focused on growth as we remain disciplined in our allocation of capital.”

Cannabis Market Outlook

In 2020, the legal cannabis market was valued at approximately $23 billion, and it is expected to top $73.6 billion in revenue by 2027, growing at a CAGR of 18.1% during the forecast period (https://ibn.fm/LdkhG). One of the biggest factors driving the cannabis market’s growth is legalization around the world.

As cannabis sales generally increased during the pandemic, Chalice Brands achieved record financials for Q4 2020, reporting quarterly revenue of $5.5 million, a year-over-year increase of 53%. The fourth quarter of 2020 also marked the company’s first quarter with positive adjusted EBITDA, reporting approximately $342,000 (https://ibn.fm/QMqrF).

Chalice Brands is uniquely positioned to capitalize on the growth of both the medicinal and recreational marijuana market segments through a rich product offering that successfully addresses current consumer needs.

Management Team

Jeff Yapp is the CEO and President of Chalice Brands Ltd. He has created a culture at Chalice Brands that operates under his mantra of ‘Crawl, Walk, Run’. He is an accomplished entrepreneur and corporate executive who has built a successful career through his ability to recognize opportunity, even when it isn’t obvious. Mr. Yapp has an extensive background in retail, marketing and entertainment. In the past, he has been committed to bringing innovation to Fortune 25 companies such as Microsoft, Kraft Foods, PepsiCo and more. As a strategic partner for Microsoft, he is an integral driver of growth for online and retail operations. He graduated with honors from the University of Michigan, majoring in Business Administration. He also graduated with honors from JL Kellogg School of Management at Northwestern University.

John Varghese is the Executive Chair of Chalice Brands and is responsible for all capital markets initiatives at the company. His background is in mergers and acquisitions, investing, operations and capital markets, with professional experience that ranges from private equity, venture capital and investment banking to senior management positions and director roles in both private and public companies. He has served on over 20 boards, acting as the chairman of six of them.

Andrew Marchington is the company’s CFO. His public accounting career experience includes time with start-up, high-growth and enterprise-level organizations, including five years of prior cannabis industry experience. He has a rich understanding of the priorities and best practices within accounting, finance and management. Mr. Marchington’s past experience includes time with companies like Deloitte, Moss Adams, Cambia Health Solutions and C21 Investments.

John Ford, Chalice Brands’ Chief Revenue Officer and VP of Retail, is a seasoned and dynamic retail leader with extensive experience in the retail industry who has led the launch of major retail brands such as Apple and Microsoft in China and Australia. His goal is to help retailers transition their businesses to modern experiential locations where customers can engage with products and brands in new ways. At Apple, Mr. Ford was the only field expat sent to launch Apple Retail in China. He set several records for Apple while in China, not just in sales but also in inventory management and employee turnover. Mr. Ford left Apple to lead Microsoft’s international retail expansion, where he also managed its e-commerce presence.

Chalice Brands Ltd. (CHALF), closed Friday’s trading session at $0.9699, up 7.7667%, on 24,525 volume with 48 trades. The average volume for the last 3 months is 68,200 and the stock's 52-week low/high is $0.0502/$2.02629995.

Recent News

• Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF) - Chalice Farms to Celebrate Cannabis Industry Holiday, National Oil Day, With Discounts on Concentrates, Dab Bus Pop-Up Experience and Collaboration with Local Artist
• 420 with CNW - State Cannabis Regulators Discuss Effects of Legalization with Members of Congress
• Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF) Expands Position in Oregon Cannabis Market Showing 150% Sales Growth

Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2)

The QualityStocks Daily Newsletter would like to spotlight Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2).

Excellon Resources Inc. (TSX: EXN) (TSX: EXN.WT) (NYSE: EXN) (FRA: E4X2) ("Excellon" or the "Company") is providing an update on the legal action in Mexico disclosed on December 5, 2019 in respect of the La Antigua mineral concession ("La Antigua") that is part of the Evolución Property in Zacatecas . La Antigua was included in Excellon's acquisition of Silver Eagle Mines Inc. ("Silver Eagle") in 2009 and includes a portion of the Evolución mineral resource at Miguel Auza . The concession is subject to an exploration and exploitation agreement with purchase option (the "Agreement") dated December 3, 2006 between San Pedro Resources SA de CV ("San Pedro", now a subsidiary of Excellon) and the owner (the "Plaintiff") that provides, among other things, for a minimum payment of US$2,500 plus value added tax per month (the "Advance Royalty") and the payment of a 3% net smelter return ("NSR") royalty. San Pedro has the right to purchase absolute title to La Antigua including the NSR royalty upon payment of US$500,000 . San Pedro has accrued the Advanced Royalty on an ongoing basis and the Agreement currently remains in force.

Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) (“Excellon” or the “Company”) is a silver and base metals producer with precious metal exploration and development projects in Mexico, Idaho and Germany. Since being founded in 1987, the Company has been advancing a precious metals growth pipeline focused on creating wealth for its stakeholders by realizing strategic opportunities in the silver and gold markets.

Excellon is an active and influential member of the Mining Association of Canada (“MAC”). The Company implements a practical, best-in-class management system that addresses the safety, health, security, environmental and community aspects of its operations, per the UN Sustainable Development Goals. On each project, the Company incorporates MAC’s Towards Sustainable Mining Initiatives and other world-class best practices with the objective of constantly improving its safety systems, training and hazard recognition.

Precious Metals Growth Pipeline

The Company is advancing a precious metals growth pipeline that includes: Platosa, Mexico’s highest-grade silver mine since production commenced in 2005; Kilgore, a high-quality gold development project in Idaho with strong economics and significant growth and discovery potential; and an option on Silver City, a high-grade epithermal silver district in Saxony, Germany, with 750 years of mining history and no modern exploration.

Maintaining and developing this pipeline presents the Company with enhanced opportunities in the expanding precious metals market, which was valued at $193.3 billion worldwide in 2020 (https://nnw.fm/6nv5f). This market is expected to increase at a compound annual growth rate (“CAGR”) of 9% from 2020 to 2027, resulting in an estimated $362.1 billion market size in 2027 (https://nnw.fm/6nv5f). Global market demand was calculated at 22,581.8 tons in 2020 and is expected to grow to 36,501.1 tons in 2027, achieving a CAGR of 3.5% (https://nnw.fm/6nv5f).

Excellon reported strong results in terms of both production and average pricing at the end of Q4 2020, including:

• Silver – 355,581 oz – $24.46
• Lead – 2,223,465 lbs. – $0.87
• Zinc – 2,452,728 lbs. – $1.21

Compared to Q4 2019, Excellon’s silver production increased by 37%, lead increased by 32% and zinc increased by 19% in Q4 2020 (https://nnw.fm/4C0P7).

Platosa Mine – Silver, Lead, Zinc – Production, Development & Exploration

The Platosa Mine is located 5 km north of Bermejillo, Durango, Mexico, on a 14,000-hectare property. The mine commenced production in 2005 as an underground operation and is 100% owned and operated by Excellon. The Company is mining massive sulfide ores rich in silver, lead and zinc from a series flat-lying massive sulfide bodies (mantos) in a carbonate replacement deposit system. Historically, the mining method was a modified room and pillar method, which transitioned to cut-and-fill in recent years and overhand-cut-and-bench in 2020. The ore produced from the mine is transported 200 km south for processing at the Company’s 100% owned Miguel Auza mill.

Kilgore Project – Gold – Exploration & Resource Growth

The Kilgore Project is located in Clark County, situated in eastern Idaho in the United States. The project area is 100% owned and operated by Excellon. While still in the exploration and development phase, the primary target on the 13,627-acre site is an epithermal gold system. The property itself has historical mining that dates back to the 1930s, with modern mineral exploration beginning in the 1980s. The Kilgore Project displays characteristics similar to Kinross Gold’s Round Mountain Mine, which has produced more than 15 million ounces of gold since operations began in 1977.

Evolución Project – Mineral Processing, Resource Growth & Exploration

The Evolución Project is located in Miguel Auza, Zacatecas, Mexico, and hosts a large gold, silver, lead and zinc epithermal within a 45,000-hectare property that is 100% owned by Excellon. The site includes a processing facility with a mill and flotation circuit which processes ore from Excellon’s Platosa mine. The facility has a capacity of 800 tons per day, with a 650 ton-per-day ball mill in operation and a second 150 ton-per-day ball mill on standby. Excellon is looking at opportunities for toll milling, expansion and economic study of the mineral resource and grassroots exploration. Importantly, the project covers an unexplored 35-kilometer strike of the Fresnillo silver trend, the richest silver belt in the world.

Silver City Project – Exploration

Excellon holds an option to acquire the 16,400-hectare Silver City Project in Saxony, Germany. Initial drilling results in 2020 confirmed the presence of a high-grade, district-scale epithermal silver system over more than 12 kilometers of strike. The Company is now focused on defining wider zones of mineralization (https://nnw.fm/jMah9). Silver City was mined from the 11th to late-19th century, until Germany moved off the silver standard in 1873. The deposits in the area were exceptionally high grade, with historical records indicating grades well in excess of 1,000 g/t silver.

Oakley Project – Exploration

The Oakley Project, located in Oakley, Idaho, is an exploration project with land holdings of approximately 7,000 acres. The project hosts gold-silver, epithermal hot spring-type mineralization at two targets: Blue Hill Creek and Cold Creek, and detachment-related gold-silver mineralization at Matrix Creek. The Company has granted Centerra (U.S.) Inc. an option to earn in to a 70% interest by, among other things, spending up to US$7 million in exploration expenditures on the project prior to May 2026.

Management Team

Brendan Cahill is the President & Chief Executive Officer of Excellon Resources Inc. He was previously Vice President Corporate Development of Pelangio Exploration Inc., a junior gold exploration company active in Ghana, West Africa. Mr. Cahill is a board member of the Mining Association of Canada, Group Eleven Resources Ltd., and Kore Mining Inc. He holds a law degree from the University of Western Ontario and an undergraduate degree from the University of Toronto.

Alfred Colas is the Company’s Chief Financial Officer. Most recently, he held the title of CFO of Arch Corp., a Toronto-based private-equity investment firm. Mr. Colas has over 18 years of experience in the mining industry. He is a sitting board member for a housing corporation affiliated with the University of Toronto and is a Chartered Professional Accountant. Mr. Colas completed a Bachelor of Commerce at the University of Toronto.

Paul Keller is Excellon’s Chief Operating Officer. He has over 30 years of industry experience in mining and mine development operations. He previously served as the Senior VP of Major Projects and COO of Trevali Mining. He has experience in building mines from greenfield through permitting, design and operation. Mr. Keller holds a Bachelor of Engineering – Mining from Laurentian University.

Ben Pullinger is the Senior Vice President Geology & Corporate Development for Excellon. Ben brings over 15 years of experience in advancing projects from early stage exploration through to production. Most recently, he was Vice President Exploration at Roxgold Inc., where he made a significant contribution toward growing the 55 Zone at Yaramoko Project into a producing mine. Mr. Pullinger serves on the board of Orford Mining. He is a Professional Geologist (Ontario) and holds an Honors Degree in Geology from the University of Johannesburg.

Excellon Resources Inc. (EXN), closed Friday’s trading session at $2.25, up 2.3658%, on 54,889 volume with 189 trades. The average volume for the last 3 months is 42,806 and the stock's 52-week low/high is $2.08999991/$3.90000009.

Recent News

• Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) - Excellon Provides Update on Miguel Auza Litigation
• MiningNewsBreaks - Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) Positioned Amid Silver's Rising Demand/Declining Supply
• Metal Markets Foresee Auto Recovery of Demand as 2021 Progresses

Petroteq Energy Inc. (TSXV: PQE) (PQEFF)

The QualityStocks Daily Newsletter would like to spotlight Petroteq Energy Inc. (TSXV: PQE) (PQEFF).

Petroteq Energy ‎‎(TSX.V: PQE) (‎OTC: PQEFF) (FSE: PQCF), an integrated oil ‎company focused on the development and implementation of its proprietary oil-‎extraction and remediation technologies, plans to complete debt conversion transactions. According to the announcement, the transactions will involve two arm’s length lenders, to which PQEFF will issue 2,333,176 common shares for $0.094 per share. The transactions will be in satisfaction of $219,318.33, representing both accrued and unpaid interest under previously issued convertible debentures. The company also plans to complete debt conversion transactions with four directors and one former director. Those transactions will involve an additional 862,456 common shares offered at $0.094 per share; these transactions are calculated to satisfy $81,071.30 of accrued and unpaid director fees due on June 30, 2021. According to the announcement, the debt conversions received creditors’ consent and were determined as a means to preserve the ‎company’s cash for working capital and for use on PQEFF’s extraction technology in Asphalt Ridge, Utah. The anticipated transactions are subject to necessary approvals. To view the full press release, visit https://ibn.fm/YN3Vi

Petroteq Energy Inc. (TSXV: PQE) (PQEFF) is a Canadian-registered, publicly traded company engaged in the development and implementation of proprietary technologies for the environmentally safe extraction of heavy oils from oil sands, oil shale deposits and shallow oil deposits. The company is focused on oil sands exploration and production on mineral leases in Vernal, Utah, and in expanding production capacity at its Asphalt Ridge heavy oil extraction facility in Utah.

Petroteq Energy’s patent-pending application is a closed-loop, solvent-based process, which results in significantly lower per-barrel production costs than those incurred with traditional hot water-based oil sands extraction technologies. This green technology utilizes a small, modular footprint, produces no greenhouse gases, requires no high temperatures, leaves only clean dry sand, and could be deployed to unlock heavy oil deposits located around the world.

The Company’s Asphalt Ridge mineral lease on 2,500-plus acres in northeastern Utah features a large contingent oil sands resource base with an estimated 87 million barrels of oil equivalent. In 2015, the company produced 10,000 barrels of oil from the Utah location and plans to increase production are underway. Utah holds over 32 billion barrels of undeveloped oil sands resources, which are also known as “oil-wet” deposits containing a mixture of sand and a dense, extremely viscous form of petroleum referred to as bitumen or tar. A recent upswing in developing domestic energy sources has intensified interest in technological advances such as Petroteq’s Clean Oil Recovery Technology (CORT) System.

The Company continues to evaluate the development of other medium to heavy oil exploration, production and recovery projects on a global basis through a variety of structured agreements. These opportunities or other arrangements with private and governmental entities that utilize Petroteq Energy’s proprietary licensed technologies are expected to generate a significant return on investment.

The Company’s management team, board of directors and officers form an invaluable cross-section of industry leaders with extensive experience ranging from chemical engineering and solvent research, business development, international project management, entrepreneurial achievements, and senior management for global energy companies in North America and the Middle East. This impressive knowledge base covers both conventional and unconventional oil and gas projects and production, both in upstream and downstream industry sectors.

Petroteq Energy is also participating in a blockchain initiative aimed at solving the global transaction needs of the oil and gas industry through the development of PetroBLOQ. PetroBLOQ recently joined the Enterprise Ethereum Alliance (“EEA”), the world’s largest open-source blockchain initiative. Membership with the 200-member EEA represents a wide variety of industries and offers 14 industry-focused, member-driven working groups.

“Joining this community of forward-looking enterprises and blockchain innovators is an important step for PetroBLOQ as we develop transformative solutions for the oil and gas industry,” said Petroteq Energy Chairman Alex Blyumkin.

In addition, Petroteq has joined the American Petroleum Institute (API). The API is the only national trade association representing all facets of the oil and natural gas industry, promoting safety across the industry globally and influencing public policy in support of a strong, viable oil and natural gas industry.

“API has led the development of operating standards for our industry, and we look forward to contributing our experience with oilfield technologies in addition to introducing our PetroBLOQ platform to its members throughout the supply chain,” Blyumkin previously stated.

Petroteq Energy Inc. (PQEFF), closed Friday’s trading session at $0.148, up 7.8324%, on 2,419,340 volume with 316 trades. The average volume for the last 3 months is 3.483M and the stock's 52-week low/high is $0.024499999/$0.249500006.

Recent News

• Petroteq Energy Inc. (TSXV: PQE) (PQEFF) - InvestorNewsBreaks - Petroteq Energy Inc. (TSX.V: PQE) (OTC: PQEFF) (FSE: PQCF) Outlines Planned Debt Conversions
• Petroteq Announces Debt Conversions
• Petroteq Energy Inc. (TSX.V: PQE) (OTC: PQEFF) (FRANKFURT: PQCF) Extracted Oil Tagged and Gauged by Buyer; Company Enters Non-Exclusive Multi-Site License Agreement

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

Researchers have made a new discovery in a fatal and aggressive childhood cancer known as Ewing sarcoma, which could possibly help hinder the spread of cancer cells. This new discovery offers new insights into what causes the process that enables cancer cells to survive as they travel through the bloodstream of an individual, spreading beyond the primary tumor site. Scientists with BC Cancer and the University of British Columbia have discovered that this particular type of cancer cells develop a shield that protects them from the bloodstream’s harsh environment as they metastasize. The researchers’ findings were reported in “Cancer Discovery.” With companies such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP) engaged in the development of novel remedies for primary as well as metastatic cancers, which afflict not just the brain but also the central nervous system, any cancers detected early in childhood could soon be stopped in their tracks.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Friday’s trading session at $1.82, off by 4.2105%, on 841,003 volume with 2,829 trades. The average volume for the last 3 months is 463,846 and the stock's 52-week low/high is $1.59000003/$4.46000003.

Recent News

• CNS Pharmaceuticals Inc. (NASDAQ: CNSP) - Researchers Find That Early Childhood Cancer Discovery May Prevent Metastasis
• InvestorNewsBreaks - CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Business Update, Progress on Driving Berubicin's Development
• Global Glioblastoma Multiforme (GBM) Treatment Market Could Reach Nearly $1.8 Billion By 2027

Ideanomics Inc. (NASDAQ: IDEX)

The QualityStocks Daily Newsletter would like to spotlight Ideanomics Inc. (NASDAQ: IDEX).

• Despite the worldwide economic difficulties imposed by the pandemic during the past year, new efforts at electric vehicle adoption are on the rise
• Ideanomics recently announced 100 percent acquisition of EV tractor manufacturer and distributor Solectrac Inc., which will grant it premium positioning in the agriculture industry’s growing interest in zero-emissions vehicles
• Ideanomics is also celebrating the launch of Technology Metals Market (“TM2”) trading using Nasdaq’s cloud-deployed matching technology for real-time pricing

Consumer interest in reducing the harmful effects of pollutants on the earth’s climate globally has led to a resurgence of electric-driven automotive technology in the world’s marketplace for private and commercial vehicles, nearly a century after the once-dominant electric vehicle industry became virtually extinct amid lower prices and mass production gains for gas-powered internal combustion engines (“ICEs”) (https://ibn.fm/1wJMo).  While the United States has lagged somewhat in electric vehicle (“EV”) adoption compared to China and Northern Europe, and the COVID-19 pandemic has had a detrimental effect on new automotive sales this past year, the overall number of EV registrations in the United States still rose 36 percent during the first four months of 2021, according to an Automotive News report, and on a YOY basis for that period EV registrations rose 95 percent from 2020 (https://ibn.fm/im2Jd). New York-based company Ideanomics (NASDAQ: IDEX) is among a new wave of organizations injecting an estimated $16.3 billion overall into the EV start-up market this year — 28 per cent more than last year, according to market research company CB Insights (https://ibn.fm/QmWgH). 

Ideanomics Inc. (NASDAQ: IDEX) is a global company facilitating the adoption of commercial electric vehicles and supporting next-generation financial services and fintech products. Ideanomics is currently divided into two divisions – mobility and capital. These divisions provide shareholders with access to disruptive and high-growth opportunities.

The company expects 2021 to be another growth year after it raised approximately $400 million over the past six months. This funding has already been put to good use with acquisitions of Wireless Advanced Vehicle Electrification (WAVE) and Timios. With roughly $200 million still on the balance sheet, Ideanomics continues to look for new investments and acquisitions in revenue-based opportunities focused on EV and fintech businesses.

Founded in 2004, Ideanomics is headquartered in New York, New York, with additional offices in Hangzhou, Beijing and Qingdao, China. Its current operations span the United States, China, Ukraine and Malaysia.

Ideanomics Mobility

Ideanomics Mobility is focused on the EV market. The global commercial EV market was valued at $34.7 billion in 2018 and is expected to grow at a CAGR of 39.9% through 2022 to reach a total of $132.73 billion (https://ibn.fm/pPrf4). According to a survey by Grand View Research, the global EV charging infrastructure market is also expected to grow and reach $144.97 billion in 2028, expanding at a CAGR of 33.4% from 2021 to 2028.

This growth is expected to be driven by increased support of electric vehicles from the public, as well as the current U.S. administration, which has a goal of achieving a 100% clean-energy economy.

The Ideanomics Mobility unit consists of five companies:

• Mobile Energy Global (MEG) – Wholly owned China-based service provider of the Sales-to-Finance-to-Charging (S2F2C) business model to assist commercial fleet operators on EV enablement. Recent sales include 2,000 units of D1, BYD’s custom electric ride-hailing vehicle.
• Medici Motor Works – Wholly owned North America division. MMW will develop zero-emissions specialty vehicles, trucks, buses and vans for the North American market.
• Wireless Advanced Vehicle Electrification (WAVE) – Wholly owned Utah-based commercial EV charging technology company with a specialized offering of in-ground wireless charging for commercial vehicles. WAVE’s chargers power the Antelope Valley Transportation Authority, the largest municipal EV bus system in the country. Its revenue for 2020 exceeded $7 million, and it boasts a robust pipeline for 2021 and beyond.
• Treeletrik – Majority investment in Malaysian-based OEM will service a high-demand market – electric delivery mopeds. Treeletrik has obtained certifications in Thailand and Indonesia, with orders secured for 2021. Its North American marketing program is expected to commence in 2021. As a part of the ESG initiative, one tree will be planted for every unit sold.
• Solectrac – Minority investment in California-based electric tractor company. Solectrac manufactures 100% electric tractors to benefit farmers, crops and the planet at a time when the agriculture market remains virtually unaddressed by EV solutions.
• Silk EV – Minority investment in hyper car and performance car design company, which provides access to the high-end battery and charging technology development ecosystem.

Ideanomics is generating EV revenue from its Sales to Financing to Charging (S2F2C) business model, which features three operating areas:

1. Vehicle and Battery Sales: Medici, Treeletrik and Solectrac cover three key market segments
2. Financing, Leasing and Insurance: Offering financial services to fleet customers, commission delivery and origination fee-based revenue
3. Charging and Energy Services: Offering charging as a service, battery swap programs and WAVE wireless charging products

Ideanomics Capital

Ideanomics Capital is focused on providing disruptive fintech solutions across the entire board of financial services, ranging from financial markets to digital securities and assets to mortgages and more. More mainstream institutions and a growing number of companies have increased their digital securities services, along with institutional investments boosting bitcoin and the emergence of favorable regulatory developments, creating ample opportunities for widespread adoption of financial technologies.

Additionally, the U.S. real estate industry is ripe for technologization, as it currently is fragmented, antiquated, opaque and largely untouched by tech innovation. However, the expanding market, with U.S. home sales expected to grow 21.9% in 2021, and the increased digitization of all business spaces are expected to promote a digital-first experience as the new industry standard this year and beyond (https://ibn.fm/DwsUv).

The Ideanomics Capital unit consists of five companies:

• Timios – Wholly owned subsidiary bringing real estate into the 21st century by providing value-add, fee-based services addressing the title and closing process of home buying and mortgage transactions. Timios works to create transparency and efficiency within the market. Timios ended 2020 as a cash flow and EBITDA positive business.
• The Delaware Board of Trade (DBOT) – Wholly owned FINRA-regulated ATS and broker dealer based in Delaware.
• Liquefy – Minority investment bringing innovation to investment in real assets with blockchain technology by increasing efficiency in fractional ownership, lowering entry to investment barriers and unlocking liquidity in assets that were previously illiquid.
• Technology Metals Market (TM2) – Minority investment in UK company delivering a direct investment and trading market for technology metals with a newly accessible technology metals asset class for inventory diversification. The traded metals are 100% backed by physical metals.
• Intelligenta – Investment providing AI and machine learning solutions for financial institutions and regulators.

Management Team

Alf Poor is Ideanomics’ Chief Executive Officer. He is a client-focused and profit-driven executive who has a track record of success in rapidly growing technology companies and large, multi-national organizations. Mr. Poor’s expertise includes business planning, financing and creating and implementing corporate governance policies, as well as handling management across organizations. His specialization is working with cross-border and multi-national startups. Before taking the CEO role at Ideanomics, he was the CEO for Global Data Sentinel.

Conor McCarthy is the company’s Chief Financial Officer. He is a strategic and operationally oriented management-level professional. His extensive international experience is within the fintech, data science and advertising technology sectors. Mr. McCarthy has experience with public companies, PE, and VC-backed firms. His specializations are financial and management reporting, planning and analysis, financial modelling, performance metrics, KPIs, venture borrowing, Series A equity funding, ERP system implementation, international business operations, and acquisition due diligence and integration. Before joining Ideanomics, Mr. McCarthy most recently held a CFO position at OS33. Prior to that, he was CFO for Intent Media Inc.

Kate Lam is the company’s Managing Director of Financial Products. She is highly regarded for her fixed income capital marketing skills across Asia and the United States. Ms. Lam has over 25 years of experience in the financial markets industry, dealing with many asset classes and clients. Having spent a few years in the fintech startup industry, her skills bridge the gap between traditional financial assets and new technological innovations. She has held senior management positions at Bear Sterns, Deutsche Bank and Standard Chartered Bank.

Keith Byers is Ideanomics’ Senior Vice President of Operations. He has extensive experience managing strategic relationships with key clients and deepening the relationships through innovation and successful engagement strategies. Before Ideanomics, Mr. Byers was the Managing Partner and Head of Operations for Gain Theory. He has a Master of Arts – MA, Economics from Heriot-Watt University and a Master of Science – Economics from The University of Edinburgh.

Tony Sklar is the company’s Senior Vice President of Investor Relations. He is a communication strategist and has worked for multi-faceted companies with global operations. Mr. Sklar handles omni-channel distribution using intelligence platforms and data insights for strategic planning, international expansion and marketing channels. His specialties include project management with digital strategy and transformation, ICO, marketing, blockchain and strategic partnerships. In addition to his role with Ideanomics, he is also a board member for the Delaware Board of Trade and the host and senior technology reporter for Far From TV.

Ideanomics Inc. (IDEX), closed Friday’s trading session at $2.66, off by 4.3165%, on 14,377,275 volume with 39,330 trades. The average volume for the last 3 months is 20.257M and the stock's 52-week low/high is $0.800000011/$5.5300002.

Recent News

• Ideanomics Inc. (NASDAQ: IDEX) - Ideanomics Inc. (NASDAQ: IDEX) Boosts EV Tractor Acquisition to 100 Percent, Anticipating Growing Potential for Environmental Awareness in Agriculture Industry
• InvestorNewsBreaks - Ideanomics Inc.'s (NASDAQ: IDEX) Solectrac Appoints Agriculture and Construction Industry Veteran as CEO
• GreenCarNewsBreaks - Ideanomics Inc.'s (NASDAQ: IDEX) Business Vitality Demonstrated in Robust Growth

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF)

The QualityStocks Daily Newsletter would like to spotlight Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF).

• In an official statement dated June 24, 2021, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) confirmed that it would participate in the Psych Investor Summit: Research and Development. The virtual event, scheduled on Wednesday, July 7, 2021, from 11:50 a.m. to 12:50 p.m. EDT, will focus on the psychedelics industry, mainly showcasing the latest research and development within the sector (https://ibn.fm/cihuB). The event is also intended to expand businesses currently looking for capital, mainly by directly delivering the industry’s most promising opportunities to funds and investors.
• Research conducted by scientists from the University of British Columbia has discovered evidence that men who have used psychedelic substances in the past have decreased chances of being involved with violence against their partners. In the study, which was reported in the “Journal of Psychopharmacology,” the scientists note that their findings do not apply to women. These studies highlighting the positive behavioral effects of psychedelics are likely to embolden entities such as Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), which is engaged in developing psychedelic medicines aimed at addressing some of the most drug-resistant mental health conditions.

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) is a pharmaceutical company focused on developing clinical-stage compounds for diseases with high unmet medical needs through accelerated regulatory pathways.

The company was founded in 2019 and is headquartered in San Diego, California.

Innovative Drug Pipeline

Tryp’s current focus is on advancing its two drug development platforms: its Psilocybin-for-Neuropsychiatric Disorders (PFN™) program targeting fibromyalgia, eating disorders and chronic pain conditions; and razoxane for soft tissue sarcomas. The company intends to explore opportunities to monetize these platforms after generating Phase 2b clinical data.

The company’s development plans cover three strategic initiatives:

• Develop: Tryp intends to utilize the FDA’s 505(b)(2) regulatory pathway with available third-party preclinical data to shorten the timelines and lower the cost of its development programs.
• Protect: Tryp plans to utilize regulatory exclusivity, patents, trade secrets and proprietary know-how to protect the commercial lifespan of its drug candidates.
• Monetize: Tryp intends to seek out licensing, acquisition and co-development opportunities for drug candidates following their Phase 2 stages of development.

PFN™ Program

Through its PFN™ program, the company is focused on developing psilocybin-based drug therapies for certain neuropsychiatric disorders that have distinct advantages over other drugs currently on the market or in development. These advantages include:

• Increased efficacy
• Natural blood-brain barrier penetration
• Enhanced safety and toxicity profiles
• Reduced risk of abuse
• Reduced risk of addiction

Tryp’s PFN™ program features its lead drug candidate, TRP-8802. The company’s initial indication for TRP-8802 is fibromyalgia.

Fibromyalgia is believed to be a neurosensory disorder characterized in part by abnormalities in pain processing by the central nervous system. The three drugs with FDA approval for the treatment of fibromyalgia are Pregabalin (Lyrica®), Duloxetine (Cymbalta®) and Milnacipran (Savella®), which are only effective for a portion of patients suffering from the condition.

Tryp plans to seek FDA approval to proceed directly to Phase 2 clinical trials evaluating TRP-8802 as a treatment for fibromyalgia based on existing preclinical and clinical data for the active pharmaceutical ingredients in TRP-8802.

Tryp’s pipeline of indications for TRP-8802 also includes eating disorders and certain forms of chronic pain. The company expects to initiate Phase 2a clinical trials in these areas in 2021.

Tryp recently partnered with Albany Molecular Research Inc. (“AMRI”) for the manufacture of the company’s synthetic psilocybin using proprietary methods. AMRI has initiated the process of manufacturing a 200g non-GMP demonstration batch of psilocybin and will produce a batch of GMP psilocybin in mid-2021. As the holder of the Drug Master File, Tryp expects to be the only U.S.-based manufacturer of synthetic psilocybin in the industry.

Razoxane

Tryp’s second drug candidate, TRP-1001 (razoxane), is being developed as a treatment for soft tissue sarcomas and has been evaluated in multiple Phase 2 clinical trials conducted by clinicians unaffiliated with Tryp. The company believes that existing clinical data regarding razoxane will likely allow TRP-1001 to be studied in a Phase 2 trial without the need for extensive preclinical or Phase 1 trials.

Sarcomas are rare tumors that are derived from connective tissues in the body and comprise 7% of all cancers in children. In 2018, an estimated 13,000 new cases of soft tissue sarcoma were diagnosed, with the tumors resulting in over 5,000 deaths during that year in the United States alone (https://ibn.fm/nWOGq).

Market Outlook

With its drug development programs targeting multiple indications, Tryp is well positioned to capitalize on growth opportunities spanning a range of therapeutic markets. The global oncology drugs market, in particular, represents a sizable opportunity.

In 2018, oncology indications accounted for 25% of all drug sales, representing approximately $151 billion in market revenues. By 2024, spending on oncology-targeted therapeutics is expected to top $200 billion and account for roughly 30% of total drug sales, according to a study by Cowen Equity Research (https://ibn.fm/9iZhM).

Valued at $764 million in 2020, the global fibromyalgia treatment market presents unique opportunities for development due to the limited number of approved therapies. With treatment trending upward, the market is expected to grow at a CAGR of 9.2% and reach $1.4 billion in value by 2027 (https://ibn.fm/G66e7).

Management Team

Greg McKee is the Chairman and CEO of Tryp Therapeutics. He has more than 20 years of life sciences management and venture investment experience that he brings to the company. Before taking his role at Tryp, he was the founder of Torrent Ventures, an early-stage digital health and medical technology venture fund. Mr. McKee also served as the CEO of CONNECT, the largest Southern California start-up accelerator. Before this, he was the chairman, president and CEO of then publicly traded Nventa Biopharmaceuticals, which successfully merged with Akela Pharma. Mr. McKee earned a B.A. in Economics from the University of Washington, an M.A. in International Studies from The Joseph H. Lauder Institute, and an MBA from the Wharton School at the University of Pennsylvania. He has been a member of the Young President’s Organization (YPO) since 2006.

James Gilligan, Ph.D., is the company’s President and Chief Science Officer. He has over 35 years of experience in the life sciences industry, including research and development, clinical development, international regulatory affairs and manufacturing. Before joining Tryp, Dr. Gilligan was the Co-Founder and Managing Partner of The Bracken Group, a life sciences consulting firm. He was also the Co-Founder of Unigene Laboratories, which develops technology for the recombinant manufacture of peptide hormones. Dr. Gilligan received his Ph.D. in Pharmacology from the University of Connecticut and a MSIB from Seton Hall University. He continued his post-graduate education at the Roche Institute of Molecular Biology.

Tom D’Orazio is the Chief Operating Officer of Tryp Therapeutics. He has extensive experience in leading the development and commercialization of vaccines, drugs, radiopharmaceuticals and biologics. His prior leadership experience has been in commercial planning, marketing, partnership and business development roles. He was formerly the CEO of ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), where he led the transition from a private company to a public one. He co-founded and served as CEO of Superna Life Sciences, a specialty-pharma company focusing on niche drugs for cancer patients in Canada. Mr. D’Orazio has an MBA from Vanderbilt University with a primary focus in both finance and marketing and a B.Sc. in chemistry from Loyola University of Chicago.

Luke Hayes is the company’s Chief Financial Officer. He has played an active role in the life science industry for over 20 years with technology transfer, venture capital and finance experience. His career started with business development for Dow Chemical (NYSE: DOW), with responsibility for pharmaceutical customers such as Eli Lilly and AbbVie. Mr. Hayes has spent more than a decade doing venture capital investing while supporting companies as a director and advisor. He earned a B.S. in Chemical Engineering from Brigham Young University and an MBA from the UCLA Anderson School of Management.

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), closed Friday’s trading session at $0.43, off by 2.2727%, on 74,213 volume with 40 trades. The average volume for the last 3 months is 75,242 and the stock's 52-week low/high is $0.392599999/$1.03999996.

Recent News

• Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) - Study Finds Men Who Use Psychedelics Less Likely to Be Violent to Their Partners
• Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Share its Drug Development Pipeline and the Company's Progress in the Psych Investor Summit
• BioMedNewsBreaks - Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Collaborating to Advance Psychedelic Medicine Program

VistaGen Therapeutics Inc. (NASDAQ: VTGN)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics Inc. (NASDAQ: VTGN).

VistaGen Therapeutics Inc. (NASDAQ:VTGN) traded Friday at a new 52-week high of $3.50. Approximately 1.8 million shares have changed hands today, as compared to an average 30-day volume of 3 million shares. In the past 52 weeks, shares of VistaGen Therapeutics Inc. have traded between a low of $0.46 and a high of $3.50 and is now at $3.43, which is 646% above that low price.

VistaGen Therapeutics Inc. (NASDAQ: VTGN) is a biopharmaceutical company committed to developing and commercializing a new generation of medications that go beyond the standard of care for anxiety, depression and other central nervous system (CNS) disorders.

The company is headquartered in South San Francisco, California, the “Birthplace of Biotechnology,” among the largest cluster of biotechnology companies in the world.

New Generation Medications

VistaGen currently has three innovative CNS drug candidates in its pipeline: PH94B, PH10 and AV-101. With a differentiated mechanism of action and an exceptional safety profile in all clinical studies to date, each of VistaGen’s three drug candidates offers significant commercialization potential in multiple large CNS markets.

PH94B

Fast-acting (10-15 minutes), non-systemic and non-sedating in Phase 2 clinical studies, PH94B is a first-in-class neuroactive nasal spray that, administered in microgram doses, binds to chemosensory receptors in the nasal passage that trigger neural circuits responsible for suppressing fear and anxiety caused by stressful social or performance situations.

PH94B is currently being developed as an acute treatment of anxiety in adults with Social Anxiety Disorder (SAD). In December 2019, PH94B became the first drug candidate to be granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for development of a treatment for SAD, positioning it to potentially become the first FDA-approved fast-acting acute treatment for adults with the anxiety disorder, if planned Phase 3 studies are successful.

A successful Phase 2 program has been completed, and, after achieving consensus with the FDA in mid-2020 that the design of its Phase 3 studies of PH94B in SAD may mirror the design of the highly statistically significant (p=0.002) Phase 2 public speaking study of PH94B in SAD, the company’s preparations for pivotal Phase 3 clinical development of PH94B are underway.

To support Phase 3 development and commercialization of PH94B for anxiety disorders in large anxiety disorder markets in Asia, VistaGen recently entered into a strategic licensing and collaboration agreement with EverInsight Therapeutics, a company formed and currently funded by a large global venture capital firm, CBC Group. The company received a $5 million non-dilutive upfront license payment from EverInsight in August 2020. If Phase 3 development is successful, VistaGen is eligible to receive additional development and commercial milestone payments of up to $172 million, plus tiered royalties on sales of PH94B in Greater China, South Korea and Southeast Asia. VistaGen retains exclusive rights to develop and commercialize PH94B in all other markets.

VistaGen is also assessing potential Phase 2A clinical development opportunities to evaluate PH94B in a range of other anxiety disorders, including:

• Adjustment Disorder with Anxiety
• Generalized Anxiety Disorder
• Postpartum Anxiety
• Perioperative Anxiety
• Panic Disorder
• PTSD

PH10

PH10 is an investigational fast-acting synthetic neuroactive nasal spray with therapeutic potential in a wide range of neuropsychiatric indications involving depression and suicidal ideation. VistaGen is initially developing PH10 as a potential fast-acting, non-sedating, non-addictive new generation treatment of major depressive disorder (MDD).

Upon self-administration, a microgram-level dose of PH10 sprayed into the nose binds to nasal chemosensory receptors that, in turn, activate neural circuits in the brain that lead to rapid-onset antidepressant effects, without side effects, systemic exposure or safety concerns that may be caused by FDA-approved drug treatments for MDD, including oral antidepressants and intranasal esketamine.

In a published exploratory Phase 2A MDD study, PH10 demonstrated rapid-onset and sustained antidepressant effects without the serious psychological side effects and safety concerns of ketamine-based therapy.

Following successfully completed Phase 2A development of PH10 for MDD, the company is currently preparing for a Phase 2B program in MDD.

VistaGen is also assessing the potential for Phase 2A clinical development of PH10 in a range of other depression-related indications, including:

• Postpartum Depression
• Treatment-resistant Depression
• Suicidal Ideation

AV-101

Part of a class of new generation investigational medicine in neurology and neuropsychiatry known as N-methyl-D-aspartate receptor (NMDAR) modulators, AV-101 is an oral prodrug of 7-chloro-kynurenic acid (7-Cl-KYNA), a potent and selective NMDAR glycine site antagonist. This drug candidate has the potential to serve as an innovative treatment for MDD and multiple neurological indications where current therapies are unsatisfactory.

VistaGen is currently evaluating AV-101, in combination with FDA-approved probenecid, in a range of neuropsychiatric and neurological indications, with both MDD and Neuropathic Pain already granted Fast Track designation by the FDA. The company is assessing the combination for a potential Phase 1B study to support a potential Phase 2A program in one or more of the following indications:

• Major Depressive Disorder
• Neuropathic Pain
• Levodopa-induced dyskinesia associated with Parkinson’s disease therapy
• Epilepsy
• Suicidal Ideation

CNS Therapeutics Market Outlook

The global CNS therapeutics market is estimated to reach $130 billion by 2025. The market was valued at approximately $82.3 billion in 2017 and is anticipated to grow at a healthy CAGR of more than 5.93% from 2018 to 2025. Even before the onset of the anxiety- and depression-provoking stressors from the COVID-19 pandemic, this growth was expected to be driven by a rise in mental illnesses and increased awareness of psychiatric disorders (https://nnw.fm/K2m0s) – all likely to be amplified by the diverse impacts of the pandemic.

The two most common mental health conditions – anxiety and depression – cost the global economy an estimated $1 trillion each year. The impact of these conditions is particularly devastating among the young. Industry data suggest that approximately 20% of the world’s children and teens are affected by mental health conditions, and suicide is the leading cause of death among 15- to 29-year-olds (https://nnw.fm/oftNb).

VistaGen’s mission is to help address the unmet needs of patients suffering from CNS disorders whose current treatments are either inadequate or generate debilitating side effects and serious safety concerns, including risk of abuse and death.

“Now more than ever, the new generation anti-anxiety and antidepressant medications we are developing at VistaGen – PH94B, PH10 and AV-101 – are relevant, necessary and demand the highly-focused and passionate efforts of our team and partners, with the support of our stockholders, to advance them to patients whose lives are disrupted by anxiety and depression disorders,” VistaGen CEO and Director Shawn K. Singh said in his closing remarks at the company’s 2020 Annual Meeting of stockholders.

Management Team

Shawn K. Singh, J.D. is the Chief Executive Officer and a Director of VistaGen. He has served on the company’s board of directors since 2000. He has nearly 30 years of experience serving in numerous senior management roles across multiple industries, including private and public biotechnology, pharmaceuticals, medical devices, venture capital, contract research and development, and law. Singh has a B.A. with honors from the University of California – Berkley. He has a J.D. degree from the University of Maryland Carey School of Law. He is also a member of the State Bar of California.

H. Ralph Snodgrass, Ph.D., is the Founder, Chief Scientific Officer and Director of the company. Snodgrass has more than 20 years of experience in the biotechnology field as a senior manager. He is recognized as an expert in stem cell biology, with over 28 years of experience using stem cells as biological research tools to promote development and drug discovery. He received a Ph.D. in immunology from the University of Pennsylvania. Snodgrass has published over 50 scientific papers with more than 17 patents and a number of patent applications.

Mark A. Smith, M.D., Ph.D., is VistaGen’s Chief Medical Officer He has over 20 years of pharmaceutical industry experience, primarily with CNS drug development. Smith has been a successful leader in the discovery and development of approximately 20 investigational new drugs. He has been a part of numerous CNS-related clinical trials. Smith received a bachelor’s and Master of Science from Yale University and a Doctor of Medicine and Doctor of Philosophy in Physiology and Pharmacology from the University of California – San Diego. He completed his residency in the psychiatry department at Duke University Medical Center.

Jerrold D. Dotson, CPA, is the Vice President, Chief Financial Officer and Secretary of VistaGen. He has over 25 years of experience in senior management positions in finance and administration at both public and private companies. Dotson is a licensed CPA in California and received his B.S. degree (Cum Laude) in business administration with a concentration in accounting from Abilene Christian College.

Mark A. McPartland is the company’s Vice President of Corporate Development and Investor Relations. He has over 20 years of experience in senior management roles in corporate development and investor relations at both public and private companies. McPartland received his Bachelor’s in business administration and marketing from Coastal Carolina University.

VistaGen Therapeutics Inc. (NASDAQ: VTGN), closed Friday’s trading session at $3.39, off by 1.7391%, on 4,133,066 volume with 13,910 trades. The average volume for the last 3 months is 2.851M and the stock's 52-week low/high is $0.460000008/$3.54999995.

Recent News

• VistaGen Therapeutics Inc. (NASDAQ: VTGN) - Shares of VistaGen Therapeutics Inc. (VTGN) Rise to a New 52-Week High
• Watch for Continued Gains in Shares of VistaGen Therapeutics Inc. (VTGN)
• InvestorNewsBreaks - VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases FY 2021 Financial Results, Corporate Highlights

Nextech AR Solutions Corp. (CSE: NTAR) (OTCQB: NEXCF)

The QualityStocks Daily Newsletter would like to spotlight Nextech AR Solutions Corp. (CSE: NTAR) (OTCQB: NEXCF).

• Nextech AR Solutions, a diversified leading provider of augmented reality (“AR”) experience technologies and services, is developing a platform for creating and publishing 3D images – at scale – from 2D originals, facilitating the digital transformation of online shopping and education
• Nextech recently announced the closing of its acquisition of AI 3D image mass producer Threedy.ai in an all-stock transaction valued at $9.5 million
• The combined efforts of the companies will remove a key bottleneck for e-commerce operators and manufacturers to create 3D models of their products at scale so that they can be easily marketed online via Web AR and on other smart devices
• Nextech’s immersive learning and video conference solution announced in June supports educators’ needs in transforming traditional learning and event formats into interactive digital learning experiences

Augmented reality (“AR”) ecosystem developer Nextech AR Solutions (CSE: NTAR) (OTCQB: NEXCF) has been making a name for itself developing 3D interactive experiential solutions that it expects to enhance e-commerce’s and higher education adoption and engagement.

Nextech AR Solutions Corp. (CSE: NTAR) (OTCQB: NEXCF), based in Vancouver, Canada, is a leading provider of web-based augmented reality for e-commerce, advertising and virtual events, with technology ranging from simple 3D images to using 360-degree videos. Nextech AR provides businesses with a powerful end-to-end augmented reality platform designed specifically to increase online sales.

The company is currently pursuing four unique verticals with its innovative technology, including:

• Virtual Conference Platform: Nextech’s advanced Augmented Reality and Video Learning Experience Platform for Events leverages an SaaS model to give organizations the ability to create engaging virtual event management and learning experiences. Automated closed captions and translations for over 64 languages are available. The global virtual events market was valued at $90 billion in 2020 by Grandview Research, and it’s expected to reach more than $400 billion by 2027.
• ARitize™ for eCommerce: Launched in early 2019, the company’s SaaS platform for webAR in eCommerce serves as a ‘full funnel’ end-to-end e-commerce solution for the AR industry. The solution includes the Aritize360 app for 3D product capture, ‘Try it On’ technology for online apparel, 3D and 360-degree product views, ‘one click buy’ and much more.
• ARitize™ 3D/AR Advertising Platform: Launched in Q1 2020, this ad platform is being marketed as the industry’s first end-to-end solution leveraging 3D asset creation for 3D/AR ads. In 2019, according to IDC, global advertising spend totaled roughly $725 billion.
• ARitize™ Hollywood Studios: The studio is in development as a means of producing immersive content using 360-degree videos and augmented reality as primary display platforms.

Unique Marketing Strategy

Nextech AR’s efforts to disrupt the market for web-based augmented reality for e-commerce are supported by a unique go to market strategy. First, the company seeks to build or acquire platforms targeting a number of rapid growth industries, most notably AR, edTech, e-commerce, 3D/AR advertising and virtual & hybrid events.

After identifying these market opportunities, the company seeks to integrate new AR technologies into existing or novel platforms in an effort to secure market share and promote growth. These technologies include WebAR, Human Holograms, 360 Portals, ScreenAR, Genie in the bottle and AiRShow.

Nextech AR then aims to leverage these platforms to land and expand partnerships with a number of blue chip customers. The company’s current customer base includes the likes of Amazon, Johnson & Johnson, ViacomCBS, Toyota and Carnegie Mellon University.

Growth Capital

Nextech AR generates revenue through a software-as-a-service model from technology services, delivery of service revenue and sales of products through e-commerce.

As noted in its latest investor presentation, the company achieved record bookings in Q4 2020 of $7.3 million (estimated), marking a greater than 275% year-over-year increase. The company also realized greater than 235% revenue growth for calendar 2020, reporting $20 million for the 12-month period. Nextech AR attributes its 2020 increase in revenues to the contracts secured with new customers, expanded agreements with existing customers and additional conversions from e-commerce channels.

With its newly launched 3D ad network now bolstering its operations, Nextech AR is projecting revenues in excess of $50 million for 2021.

Recent Company Highlights

• February 16, 2021: The company announced it has hired Zak Mcleod, formerly of Fastly, as its new Senior Director of Sales – EMEA. The company also announced that Rory Ganness, formerly of Salesforce.com, has joined the Nextech team as Director of Enterprise Sales – North America.
• February 11, 2021: The company announced the launch of version 2.0 of its AiR Show app, an application that turns top music artists into interactive ‘live’ holograms, providing an immersive and engaging AR experience.
• February 8, 2021: The company announced the launch of new standardized chat features within its Virtual Experience Platform (VXP) and recently-launched ARoom collaborative streaming solution. Nextech will also offer the chat platform as a stand-alone SaaS service externally, increasing the company’s revenue potential for 2021.
• January 26, 2021: The company announced, in partnership with ARB Meetings and Events, it has signed a six-figure annual contract to supply its InfernoAR video conferencing and virtual events platform to NAMD.
• January 25, 2021: The company announced that Strategic Site Selection (SSS), a 15 year old site selection leader in the meeting and events industry, has selected Nextech AR as a preferred channel partner, making Nextech’s industry leading virtual experience platform and services available to SSS clients.
• January 20, 2021: The company announced that Microsoft’s Azure Cloud Services platform will be a standard offering across its virtual experience platforms and consumer apps, enabling hyper-scalable, secure and immersive events and applications for users.
• January 15, 2021: The company signed a renewal agreement with Poly with an initial value of $470,000 for a six-month term and the potential for additional revenue after the six months.

Management Team

Evan Gappelberg is CEO and Founder of Nextech AR. He is an experienced operating executive specializing in creating, funding and running hyper-growth startups in both the public and private sectors. Notably, he took Take-Two Interactive Software Inc. (NASDAQ: TTWO) public with a market cap of $30 million and played a key role in guiding its growth to a current market cap of roughly $14 billion. Mr. Gappelberg has extensive experience as both a hands-on operating executive and a public markets professional.

Paul Duffy is the company’s President. He is a serial entrepreneur with over 25 years of experience in successfully starting, expanding, diversifying and selling global technology companies. Mr. Duffy is the creator of the HumaGram and inventor of the patent for Holographic Telepresence over the Internet (TOIP).

Augen Winschel is the COO of Nextech AR. He is an 18-year SAP executive with over 20 years of leadership experience in the areas of business management, business operations, marketing, product management, digital business and enterprise artificial intelligence.

Kashif Malik, CPA, CA, is the company’s CFO. He has over 15 years of financial experience spanning IPOs, M&A activity, corporate restructuring and capital raising. Mr. Malik has worked globally with public and private companies, including Merck & Company Inc. (NYSE: MRK), Real Matters Inc. (TSX: REAL) and Constellation Software Inc. (TSX: CSU). He obtained his Chartered Accountant designation while working at Deloitte.

Hareesh Acchi is the company’s President of 3D/AR Advertising. He is a 20-year Microsoft technology veteran with experience leading digital transformation and scaling businesses and enterprise organizations across the advertising industry.

Nextech AR Solutions Corp. (NEXCF), closed Friday’s trading session at $2.26, off by 4.4397%, on 86,142 volume with 203 trades. The average volume for the last 3 months is 225,038 and the stock's 52-week low/high is $1.50/$5.41120004.

Recent News

• Nextech AR Solutions Corp. (CSE: NTAR) (OTCQB: NEXCF) - Nextech AR Solutions Corp. (CSE: NTAR) (OTCQB: NEXCF) Closes Acquisition of AI Production Scaler Threedy.ai, Sees Important Step in E-commerce Evolution
• InvestorNewsBreaks - Nextech AR Solutions Corp.'s (CSE: NTAR) (NEO: NTAR) (OTCQB: NEXCF) (FSE: N29) EdTechX Enabling Valuable Digital Learning Experiences
• InvestorNewsBreaks - Nextech AR Solutions Corp. (CSE: NTAR) (NEO: NTAR) (OTCQB: NEXCF) (FSE: N29) Closes Acquisition of Silicon Valley-Based Threedy

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

• Predictive Oncology (NASDAQ: POAI) has closed on its registered direct offering (https://ibn.fm/9buhx).The offering, which totaled $21.34 million, will be a boon for the knowledge-driven company as it continues its focus on applying artificial intelligence (“AI”) to personalized medicine and drug discovery.
• Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is looking to give oncology drug developers an upper hand, thereby increasing the chances of the drugs’ success from the onset. “Raising the success rate for experimental cancer drugs starts in the laboratory, where leading-edge technology could be instrumental in providing prescient insights that ultimately result in better clinical outcomes,” reads a recent article. TumorGenesis, a subsidiary of POAI, has partnered with Swedish cell culture system company Cellevate AB. To view the full article, visit: https://ibn.fm/oOU5z

Predictive Oncology (POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow. The company has several tools that support its mission of bringing precision medicine to the treatment of cancer.

Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:

• A database of clinically validated historical and outcome data from patient tumors
• An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
• A “smart” patient-derived tumor profiling platform
• An in-house bioinformatics artificial intelligence (AI) platform
• A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
• An FDA-approved fluid collection and disposal system

Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from the company’s trove of more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies. This database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory without the use of rats or mice, allowing for the identification of biomarkers indicative of cancer. This methodology “fools” the tumor into thinking it is still in the body. As a result, the tumor reacts as it naturally would, thereby increasing the accuracy of the biomarker. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and helps categorize an individual patient’s heterogeneous tumor samples to enable development of patient-specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY® System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Competitive Advantage

Precision medicine has become the holy grail of cancer therapeutics. Data driven predictive models of tumors and their responses are critical in both new drug development and individualized patient treatment. The race has begun to model various tumors, which takes 5 to 7 years of clinical evaluation to establish historical and outcome data.

Predictive Oncology enjoys significant competitive advantage. The company already has a vast historical collection of tumors and related data, plus the ability to obtain existing associated outcome data. While others wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine to reality. Predictive Oncology already has the clinical data, including how a tumor responded to certain drugs, an in-house bioinformatics AI platform, and only needs to do the tumor sequencing. The significance is underscored by the collaboration with UPMC Magee-Women’s Hospital, designed to reveal which mutations responded to which drug then develop powerful predictive models for future testing and treatment.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Gerald Vardzel, President of Helomics, has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several small-to-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.

Dr. Mark Collins, Chief Information Officer of Helomics, has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.

Predictive Oncology (POAI), closed Friday’s trading session at $1.21, off by 6.2016%, on 4,288,647 volume with 8,499 trades. The average volume for the last 3 months is 3.369M and the stock's 52-week low/high is $0.629999995/$2.29999995.

Recent News

• Predictive Oncology (NASDAQ: POAI) - BioMedNewsBreaks - Predictive Oncology Inc. (NASDAQ: POAI) Bringing Researchers Next-Level Tools for Hard-to-Treat Diseases
• Predictive Oncology Inc. (NASDAQ: POAI) Stands Strong as Innovator, Leader in Precision Medicine
• Researchers Find Link Between Cellular Aging, Epigenetic Changes in Cancer Patients